Have your say on Xofigo (Radium 223) on the PBS

[Admin]

Have your say on Xofigo (Radium 223) on the PBS

Xofigo® (radium Ra 223), is being considered at the November 2017 Pharmaceutical Benefits Advisory Committee (PBAC) meeting for listing on the Pharmaceutical Benefit Scheme (PBS).
There is an opportunity for patients and the prostate cancer community (carers, doctors, organisations etc) to make submission directly to the PBAC.
The Australian Advanced Prostate Cancer Support Group Executive Committee will be making a submission. We will post more details of what to say in a submission in mid-September, but if you know what you wish to say now:
The preferred method is via an online form. Click this sentence to be taken to the online form. Or via email  CommentsPBAC@health.gov.au.
The consumer comments are open to until 4 October.

Some details of Xofigo treatment are in our YouTube video: Treatment for metastatic prostate cancer in the bones: